A commonly prescribed drug could be more effective than aspirin for long-term heart disease prevention. Analysis of nearly 29,000 patients with coronary artery disease (CAD) suggests the blood thinner ...
HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ('Aspire' or the 'Company'), a developer of a multi-faceted patent pending drug delivery ...
Glatt Air Techniques has conducted testing and manufacturing of Aspire's GMP Clinical Batch of its oral mucosal fast acting formulation of aspirin under both Pharmaceutical Inspection Co-operation ...
Subsequent phase involves completion of chemistry, manufacturing, and controls (CMC) testing for data to support FDA submission Company expects to commence bioavailability study in April 2025 Aspire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results